STAT’s Adam Feuerstein said via Twitter: "$SAVA – today’s updated results tell you that simulfilam is no better than a placebo in Alzheimer’s disease. that’s the most important and correct interpretation of the n=200 data from this open label study." Shares of Cassava are down 23% to $27.92 in morning trading.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAVA:
- SAVA Stumbles on Disappointing Alzheimer’s News
- Cassava Sciences falls after simufilam data for Alzheimer’s disease treatment
- Cassava Sciences announces clinical results in Phase 2 study of simufilam
- Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
- Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
